ArticleClinical and translational radiation oncology2018
Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer.
Article in Clinical and translational radiation oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial.The British journal of radiology · 2020Trial
- Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer.Small science · 2025Review
- Virtual tumor mapping and margin control with 3-D planning and navigation.Innovative surgical sciences · 2024Review
- Article
- BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial.Clinical and translational radiation oncology · 2023Article
- Feasibility and guidelines for the use of an injectable fiducial marker (BioXmarkF1000Research · 2023Article
- Evaluation of computed tomography settings in the context of visualization and discrimination of low dose injections of a novel liquid soft tissue fiducial marker in head and neck imaging.BMC medical imaging · 2021Article
- Intraoperative marking of the tumour resection surface for improved radiation therapy planning in head and neck cancer: preclinical evaluation of a novel liquid fiducial marker.Dento maxillo facial radiology · 2021Article
- Carbohydrate based biomarkers enable hybrid near infrared fluorescence andNanotheranostics · 2021Article
- Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic intervention.Science advances · 2020Article
- Evaluation of a Novel Liquid Fiducial Marker, BioXmarkCancers · 2020Article
- Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging.Radiation oncology (London, England) · 2019Article
- Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3T MRI.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019Article
- Impact of Number and Placement of High-dose Vertices on Equivalent Uniform Dose and Peak-to-valley Ratio for Lattice Radiotherapy.Journal of medical physicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0-38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.